About
Stem Cell Therapies
Areas of Focus
Categories
Stem Cell & Cellular TherapyVirginia, DC, DE & Maryland
Team (6)
Hiroaki Kobayashi, MDBoard Member
Hiroaki Kobayashi, MDBoard Member
Elixirgen Therapeutics
team_member
Jeffrey L. Cleland, PhDBoard Member
Jeffrey L. Cleland, PhDBoard Member
Elixirgen Therapeutics
team_member
Minoru Ko
Minoru Ko, MD, PhDChief Scientific Officer & Co-Founder,
Board Member
Elixirgen Therapeutics
founder
Shauna CallahanBoard Member
Shauna CallahanBoard Member
Elixirgen Therapeutics
team_member
Takamitsu Fujiu, PhD, JDGeneral Counsel
Takamitsu Fujiu, PhD, JDGeneral Counsel
Elixirgen Therapeutics
team_member
Thomas J. White, PhDBoard Member
Thomas J. White, PhDBoard Member
Elixirgen Therapeutics
team_member
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
3
As Collaborator
1
Total Enrollment
228
By Phase
PHASE2: 1PHASE1: 2PHASE1/PHASE2: 1
By Status
RECRUITING: 2ENROLLING_BY_INVITATION: 1COMPLETED: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT07219849Lead Sponsor
A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure
PHASE2Recruiting
164 participants
Started: Oct 17, 2025 · Completed: Apr 30, 2026
NCT05868499Lead Sponsor
Rollover Study From EXG-US-01
PHASE1Enrolling by invitation
12 participants
Started: Jan 1, 2024 · Completed: Jan 30, 2027
NCT04863131Collaborator
Safety and Immunogenicity of EXG-5003
PHASE1/PHASE2Completed
40 participants
Started: Apr 28, 2021 · Completed: Jan 24, 2023
NCT04211714Lead Sponsor
Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure
PHASE1Recruiting
12 participants
Started: Apr 8, 2021 · Completed: Oct 8, 2027
Locations (1)
Headquarters
Baltimore, MD, United States
Map
Loading map...